

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:
Commissioner for Patents, P.O. Box 1450
Alexandria, VA 22313 on December 15, 2005.

Frank C. Eisenschenk, Ph.D., Patent Attorney

THIRD SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT
Examining Group 1646
Patent Application
Docket No. G-029US04DIV
Serial No. 10/072,159

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Gyan Chandra
Art Unit : 1646
Applicants : Bernard Bihain, Lydie Bougueleret, Frances Yen-Potin
Serial No. : 10/072,159
Filed : February 5, 2002
Conf. No. : 2627
For : Lipoprotein-Regulating Medicaments

Mail Stop RCE
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313

THIRD SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §§1.97 AND 1.98


Sir:

In accordance with 37 CFR §1.56, the references listed on the attached form PTO/SB/08 are being brought to the attention of the Examiner for consideration in connection with the examination of the above-identified patent application. A copy of the cited reference is enclosed. However, Applicants have not submitted copies of the U.S. patents or published U.S. Patent Applications cited on attached Form PTO/SB/08 pursuant to 37 CFR 1.98(a)(2)(ii).

It is respectfully requested that the references cited on the attached form PTO/SB/08 be considered in the examination of the subject application and that its consideration be made of record.

Applicants respectfully assert that the substantive provisions of 37 CFR §§1.97 and 1.98 are met by the foregoing statement.

Respectfully submitted,



Frank C. Eisenschenk, Ph.D.

Patent Attorney

Registration No. 45,332

Phone No.: 352-375-8100

Fax No.: 352-372-5800

Address: P.O. Box 142950
Gainesville, FL 32614-2950

FCE/sl

Attachments: Form PTO/SB/08; copies of references cited therein.



PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Application Number	10/072,159	
			Filing Date	February 5, 2002	
			First Named Inventor	Bernard Bihain	
			Art Unit	1646	
			Examiner Name	Gyan Chandra	
Sheet	1	of	2	Attorney Docket Number	G-029US04DIV

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number - Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	U1	US-6,967,091	11-22-2005	Fruebis <i>et al.</i>	All
	U2	US-6,867,189	03-15-2005	Lucas <i>et al.</i>	All
	U3	US-6,566,332	05-20-2003	Fruebis <i>et al.</i>	All
	U4	US-2003-0215836	11-20-2003	Young <i>et al.</i>	All
	U5	US-2005-0069971	03-31-2005	Lucas <i>et al.</i>	All
	U6	US-2005-0054565	03-31-2005	Lucas <i>et al.</i>	All
	U7	US-2005-0003997	01-06-2005	Lucas <i>et al.</i>	All
	U8	US-2003-0224501	12-04-2003	Young <i>et al.</i>	All
	U9	US-6,946,444	09-20-2005	Bihain <i>et al.</i>	All
	U10	US-6,344,441	02-05-2002	Bihain <i>et al.</i>	All
	U11	US-6,566,332	05-20-2003	Fruebis <i>et al.</i>	All
	U12	US-2004-0067881-A1	04-08-2004	Fruebis <i>et al.</i>	All
	U13				

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)			
	F1				
	F2				

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete if Known

Application Number	10/072,159
Filing Date	February 5, 2002
First Named Inventor	Bernard Bihain
Group Art Unit	1646
Examiner Name	Gyan Chandra
Attorney Docket Number	G-029US04DIV

Sheet	2	of	2
-------	---	----	---

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R1	U.S. Patent Application Serial No. 11/132,814, filed May 19, 2005, claims only.	
	R2	Database Entrez Nucleotides, Accession No. BAA08227, a novel adipose specific collagen-like factor, February 10, 1999.	
	R3	Database Entrez Nucleotides, Accession No. D45371, Human apM1 mRNA, February 10, 1999.	
	R4	Online Mendelian Inheritance in Man database; Adipocyte, C1Q, and Collagen Domain Containing; ACDC; accessed August 24, 2005.	
	R5	BLOOMGARDEN, Z. T. "Obesity, Hypertension, and Insulin Resistance" <i>Diabetes Care</i> , November 2002, pp. 2088-2097, Vol. 25, No. 11.	
	R6	STEINBERGER, J. <i>et al.</i> "Obesity, Insulin Resistance, Diabetes, and Cardiovascular Risk in Children" <i>Circulation</i> , 2003, Vol. 107, pp. 1448-1453.	
	R7	DE JONGH, R. T. <i>et al.</i> "Impaired Microvascular Function in Obesity" <i>Circulation</i> , 2004, pp. 2529-2535, Vol. 109.	
	R8		
	R9		
	R10		
	R11		
	R12		
	R13		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.